Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut
By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...
archpaper8h
1769 Jerome
Jerome with clients Bronx Pro Group and Service for the Underserved (S:US). The brick building offers low-income and ...
Texas QB Arch Manning opens as early 2025 Heisman Trophy favorite
The early favorite for the 2025 Heisman Trophy isn’t much of a surprise. Texas QB Arch Manning has opened as the favorite at BetMGM ahead of his first season as the Longhorns’ starter. Manning is +800 ...
Arch Manning Makes His Thoughts On Jeremiah Smith Clear
"It's great," Manning answered. "I'm so excited about the partnership. Red Bull is a great brand, and when they reached out, it was just like a match made in heaven, and I'm glad ...
Crain's New York12h
FiDi-based obesity drug maker sees $1.9B IPO
Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.
Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut
Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...